Skip Navigation


NDT Advance Access originally published online on May 18, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/7/1682    most recent
gfh283v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hernández, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernández, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: 1682-1686
Nephrol Dial Transplant Vol. 19 No. 7 © ERA-EDTA 2004; all rights reserved

Editorial Comment

Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder

Domingo Hernández

Department of Nephrology, Research Unit, University Hospital of the Canary Islands, Research Institute Reina Sofia, La Laguna, Tenerife, Spain

Correspondence and offprint requests to: Domingo Hernández, Urbanización San Diego, 51, E-38208, La Laguna, Tenerife, Spain. Email: dhmarrero@hotmail.com

Keywords: cardiovascular mortality; left ventricular hypertrophy; renal transplantation

The first 150 words of the full text of this article appear below.



   Introduction
 
Renal transplantation (RT) is the treatment of choice for end-stage renal failure, but all-cause mortality is high in these patients [1]. The cardiovascular death rate is higher than in the general population, even after stratifying for age, gender and race. Moreover, left ventricular hypertrophy (LVH) is extremely common in kidney transplant recipients (50–70%) and appears to be an important determinant of survival [2]. In general, correction of the uraemic state by RT leads to regression of LVH, but in many patients cardiac growth persists, even in normotensive recipients [3]. Many risk factors of volume and pressure overload concur after RT. Additionally, other risk conditions inherent to RT, such as immunosuppressive therapy and possibly genetic factors, may contribute to perpetuate this complication. The renin–angiotensin system (RAS) plays an important role in the pathogenesis of cardiac growth. Blockade of this system by angiotensin-converting enzyme inhibitors (ACEIs) . . . [Full Text of this Article]



   Clinical significance
 


   Pathophysiology of LVH: Role of immunosuppression
 


   Can diabetes influence cardiac growth?
 


   Role of ACE gene polymorphism
 


   Preventive and therapeutic options to minimize LVH
 


   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?